Enhancement of Motor Function With Reboxetine & Transcranial Direct

Status Completed

Clinical Trial Summary

The hypothesis of the study is that combination of reboxetine/tDCS is more effective in enhancing motor functions of daily life (assessed by the Jebsen Taylor test) as compared to reboxetine and tDCS alone. The protocol is designed as a within-subject, block randomized placebo-controlled double-blind crossover study.

Clinical Trial Description

One important feature of the human brain is the ability to undergo plastic changes and reorganization after learning and lesions of the nervous system. This ability is of major importance for the treatment of functional deficits after stroke. Stroke is the major disease leading to persistent functional disabilities in Germany. However, the success rate of therapeutic interventions, especially in chronic stroke patients, is still unsatisfactory. Thus, basic science is essential to discover new therapeutic options that bear the potential for translation into clinical practice. Recent evidence is pointing to modulating the motor cortical excitability in order to enhance motor function in stroke patients. For this purpose, reboxetine as a selective reuptake inhibitor of noradrenaline and transcranial direct current stimulation have proven effective in enhancing motor functions needed for daily life activities by 10-12%. These improvements were significant compared to placebo, but still clinically unsatisfactory. Thus, this protocol aims at enhancing the excitability modulatory effect of each single intervention through the combination of reboxetine and tDCS. The hypothesis of the study is that combination of reboxetine/tDCS is more effective in enhancing motor functions of daily life (assessed by the Jebsen Taylor test) as compared to reboxetine and tDCS alone.

The protocol is designed as a within-subject, block randomized placebo-controlled double-blind crossover study. 12 chronic stroke patients with persistent functional deficits of the arm and/or hand will be included. The primary outcome measure is the time needed to fulfill all subtests of the Jebsen Taylor test. All patients undergo four different conditions in four different sessions: 1) reboxetine + verum tDCS; 2) reboxetine + sham tDCS 3) placebo drug + verum tDCS 4) placebo drug + sham tDCS. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00853866
Study type	Interventional
Source	Universitätsklinikum Hamburg-Eppendorf
Contact
Status	Completed
Phase	Phase 4
Start date	January 2009
Completion date	June 2010

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03281590` - Stroke and Cerebrovascular Diseases Registry
Recruiting	`NCT03685578` - CERENOVUS Neurothrombectomy Devices Registry
Recruiting	`NCT05591183` - CERENOVUS Neurothrombectomy Devices Registry
Completed	`NCT04465019` - Exoskeleton Rehabilitation on TBI
Completed	`NCT02827825` - Patients Undergoing Strokes Admitted in Intensive Care Requiring Neurosurgical ICU Crossing: Patient Profile and Prognosis
Recruiting	`NCT02077582` - Longitudinal MRI Examinations of Patients With Brain Ischemia and Blood Brain Barrier Permeability	N/A
Completed	`NCT01732679` - Sunnaas International Network´s Stroke Study	N/A
Terminated	`NCT01705353` - The Role of HMGB-1 in Chronic Stroke	N/A
Completed	`NCT01182818` - Fabry and Stroke Epidemiological Protocol (FASEP): Risk Factors In Ischemic Stroke Patients With Fabry Disease	N/A
Completed	`NCT00311025` - Stroke: Reduction of Physical Performance Post Stroke. Inactivity or Secondary Complications?	Phase 1/Phase 2
Withdrawn	`NCT03804125` - A Study of Adverse Events and Suspected Adverse Drug Reactions in Patients Under Apixaban for Prevention of Stroke and Systemic Embolism With Non-Valvular Atrial Fibrillation and Venous Thromboembolic Events in Patients Who Have Undergone Elective Hip or Knee Replacement Surgery
Completed	`NCT05435404` - Qualitative Study Patient & Physician Experiences Botox COVID-19
Completed	`NCT03898960` - Post Marketing Study to Evaluate the NIMBUS Device
Not yet recruiting	`NCT06087094` - A Trial of HRS-7450 in Chinese Healthy Volunteers	Phase 1
Completed	`NCT02207023` - Healthy Lifestyles After Stroke - Stroke Coach	N/A
Active, not recruiting	`NCT02017574` - Motor Learning in Stroke	Phase 0
Completed	`NCT02002390` - Efficacy and Safety of FTY720 for Acute Stroke	Phase 2
Completed	`NCT01864382` - "Core Stability" Exercises to Improve Sitting Balance in Stroke Patients	N/A
Recruiting	`NCT04447599` - Conjunctival and Retinal Vascularization and Small Vessel Disease	N/A
Recruiting	`NCT04157179` - Cerebral Oxygen Metabolism in Children	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Enhancement of Motor Function With Reboxetine and Transcranial Direct Current Stimulation — STIMBOX

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms